X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ASTRAZENECA PHARMA AJANTA PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 18.7 122.2 15.3% View Chart
P/BV x 7.5 17.4 43.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 AJANTA PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
AJANTA PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,285 133.9%   
Low Rs1,103634 174.0%   
Sales per share (Unadj.) Rs194.6189.6 102.6%  
Earnings per share (Unadj.) Rs45.2-0.2 -22,209.8%  
Cash flow per share (Unadj.) Rs50.33.8 1,308.3%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.068.6 192.4%  
Shares outstanding (eoy) m88.7725.00 355.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.35.1 143.3%   
Avg P/E ratio x31.2-4,712.7 -0.7%  
P/CF ratio (eoy) x28.1249.6 11.2%  
Price / Book Value ratio x10.714.0 76.5%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29923,988 522.4%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,5701,605 160.2%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m17,2754,740 364.5%  
Other income Rs m16692 180.6%   
Total revenues Rs m17,4424,832 361.0%   
Gross profit Rs m5,807-130 -4,474.0%  
Depreciation Rs m451101 445.3%   
Interest Rs m490-   
Profit before tax Rs m5,474-139 -3,941.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,4605 28,681.7%   
Profit after tax Rs m4,014-5 -78,862.5%  
Gross profit margin %33.6-2.7 -1,227.5%  
Effective tax rate %26.7-3.7 -727.8%   
Net profit margin %23.2-0.1 -21,637.0%  
BALANCE SHEET DATA
Current assets Rs m7,6392,726 280.2%   
Current liabilities Rs m2,7152,435 111.5%   
Net working cap to sales %28.56.1 463.6%  
Current ratio x2.81.1 251.3%  
Inventory Days Days4374 58.6%  
Debtors Days Days7941 193.0%  
Net fixed assets Rs m6,9141,035 667.8%   
Share capital Rs m17750 353.8%   
"Free" reserves Rs m11,442942 1,214.1%   
Net worth Rs m11,7211,716 683.0%   
Long term debt Rs m1490-   
Total assets Rs m14,8144,156 356.5%  
Interest coverage x112.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.1 102.3%   
Return on assets %27.4-0.1 -22,393.6%  
Return on equity %34.2-0.3 -11,546.2%  
Return on capital %46.50-  
Exports to sales %55.15.7 967.4%   
Imports to sales %6.06.5 92.9%   
Exports (fob) Rs m9,527270 3,525.9%   
Imports (cif) Rs m1,038306 338.8%   
Fx inflow Rs m10,422375 2,782.1%   
Fx outflow Rs m1,678470 356.9%   
Net fx Rs m8,744-96 -9,150.8%   
CASH FLOW
From Operations Rs m3,264-8 -40,293.8%  
From Investments Rs m-2,093-146 1,436.4%  
From Financial Activity Rs m-1,186862 -137.5%  
Net Cashflow Rs m-15709 -2.1%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 15.7 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 12,856 163.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 25, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - ALEMBIC LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS